<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Neuroscience Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles/><gtr:project url="http://gtr.ukri.org:80/projects?ref=G120%2F97"><gtr:id>8AF695DB-ED86-41AF-81CE-FA61E3080865</gtr:id><gtr:title>Regulation of synaptic inhibition under normal conditions and in ischaemia and neurodegenerative disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G120/97</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Synaptic inhibition, mediated by the -aminobutyric acid type A receptor (GABAAR), a ligand-gated chloride channel, is crucial for the control of cell and network activity in the brain. Modulating GABAAR function has major consequences for neuronal excitation and information processing in the brain. In addition, altered GABAAR function has been implicated in an increasing number of neurological and neuropsychiatric diseases. Understanding the molecular mechanisms neurons use to regulate GABAAR function will have important implications for both our understanding of how neuronal activity is controlled and how disrupted inhibition may contribute to the pathogenesis of diseases such as epilepsy, stroke, anxiety, substance abuse, depression, Parkinson?s disease and autism. One accepted means of modifying the efficacy of synaptic transmission is to change the number and/or sensitivity of postsynaptic receptors. This can be achieved by a number of mechanisms, including regulated receptor membrane trafficking, and post-translational modifications such as phosphorylation, ubiquitination or palmitoylation. The overall aim of my research is to understand better the molecular mechanisms important for regulating GABAAR function, with a particular emphasis on control of GABAAR membrane trafficking and how this may be altered under pathological conditions such as ischaemia and neurodegeneration. The main objectives of my proposal are to investigate three distinct but related questions:
(1) How do glutamate signalling and ischaemia modulate GABAAR activity, surface dynamics and membrane trafficking?
(2) What is the role of the huntingtin associated protein 1 (HAP1) in GABAAR membrane trafficking?
(3) Does disrupted HAP1 function lead to altered GABAAR activity in Huntington?s disease (HD)?
Completion of this work will provide valuable insights into how GABAAR function and synaptic inhibition are controlled under normal conditions, and how altered inhibitory neurotransmitter ptor function and trafficking may contribute to neuronal dysfunction in stroke and neurodegenerative disease. 
To answer these questions, I will use a multi-disciplinary approach combining molecular, cell biological, biochemical, imaging and electrophysiological methodologies.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1996-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>934454</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G120/97</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>